Health Care·Life Sciences Tools & Services·$8.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.46 | N/A | +35.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.46 | N/A | +35.29% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management is pleased with the earnings results and remains focused on future growth. They did not provide specific guidance for the upcoming quarters.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They highlighted ongoing investments in innovation as a key focus moving forward.
Bio-Techne's strong EPS performance, exceeding expectations by over 35%, has positively impacted investor sentiment, leading to a 6.25% increase in stock price. The lack of revenue data and guidance may raise some concerns, but management's focus on innovation suggests a commitment to long-term growth. Investors will likely be watching closely for future updates.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Feb 2, 2026